Guardion®已与Ho Wah Genting Berhad（HWGB）签署了任命书，以创建一种旨在增强免疫系统的新配方。 该配方将成为HWGB的独特品牌
圣地亚哥讯：
2020年2月26日 − Guardion Health Sciences，Inc（“Guardion” 或 “ Company”）（纳斯达克股票代码：GHSI）宣布，Ho Wah Genting Berhad（“HWGB”）是一家在马来西亚证券交易所上市的马来西亚公司。 （工业产品部门）已选择Guardion为其消费者基础开发免疫支持配方。 HWGB已与Guardion及其最近收购的子公司NutriGuard签约，以开发专有配方来满足其客户对免疫支持配方的需求。
NutriGuard的最初创始人，现在是Guardion的资深科学家顾问的Mark McCarty教授是营养强化疗法的科学验证的领导者，以增强对RNA病毒的1型干扰素反应。据信，加强1型干扰素反应可抑制病毒细胞的复制。 McCarty博士的任务是为HWGB开发此专有配方。
该配方旨在为使用者提供免疫支持和抗炎功效。该公式尚未使用或测试，也无意专门解决当前COVID-19病毒的症状。
Guardion Health Sciences首席执行官Michael Favish表示：“我们很高兴与Ho Wah Genting Berhad合作开发了专门设计用于增强免疫系统功能（即对RNA病毒的1型干扰素应答）的产品。”
Ho Wah Genting Berhad集团首席执行官拿督亚伦（Atoron Lim）表示：“我们急切希望能够提供独特的产品，以对我们的客户群提供及时有效的免疫反应。我要感谢 Guardion Health Sciences 对这一要求的协助和响应，并希望将这种急需的产品推向市场。”
About Guardion Health Sciences, Inc.
Guardion is an ocular health sciences company thar develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols. Guardion’s initial medical food product, Lumega-Z, addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardionand its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials. VectorVision® is a wholly owned subsidiary of Guardion.
Guardion has completed development of the proprietary VectorVision® CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.
About NutriGuard
NutriGuard formulates high-quality, scientifically credible nutraceuticals, which are designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions. NutriGuard uses pharmaceutical standards to establish the safety and efficacy of the products it develops and markets, and also maintains that commitment through rigorous manufacturing and quality assurance programs. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and the Company’s ability to successfully develop and commercialize its proprietary products and technologies, including acuMMUNE. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov).
The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
Guardion Health Sciences, Inc. 15150 Avenue of Science, Ste. 200 San Diego, CA 92128
Ph 858.605.9055; Fax 858.630.5543
Investor Relations Contact: Porter, LeVay & Rose, Inc.
Michael Porter
Telephone: (212) 564-4700 E-mail: [email protected]
Matthew Abenante Telephone: (212) 564-4700
E-mail: [email protected]
（图文：Guardion Health Sciences，Inc）
